CLOs on the Move

Abengoa Bioenergy Corporation

www.abengoabioenergy.com

 
Abengoa Bioenergy Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 10K-50K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details

Similar Companies

Merck KGAA

Merck KGAA is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Allylix Inc.

Allylix Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Micromet

Micromet, Inc is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Editas Medicine

What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We`re a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Our goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer. We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine `Editors`, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we`ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.

TriSalus Life Sciences

TriSalus Life Sciences is dedicated to improving patient outcomes in pancreatic and other highly intractable solid tumors. TriSalus Infusion Systems, powered by the proprietary Pressure-Enabled Drug Delivery (PEDD) approach with SmartValve technology have the potential to improve the delivery and distribution of diagnostic agents, therapeutics, and immuno-stimulants into the tumor vasculature.